Article

Mutations in the β-myosin rod cause myosin storage myopathy via multiple mechanisms

Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO 80309, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 03/2009; 106(15):6291-6. DOI: 10.1073/pnas.0900107106
Source: PubMed

ABSTRACT Myosin storage myopathy (MSM) is a congenital myopathy characterized by the presence of subsarcolemmal inclusions of myosin in the majority of type I muscle fibers, and has been linked to 4 mutations in the slow/cardiac muscle myosin, beta-MyHC (MYH7). Although the majority of the >230 disease causing mutations in MYH7 are located in the globular head region of the molecule, those responsible for MSM are part of a subset of MYH7 mutations that are located in the alpha-helical coiled-coil tail. Mutations in the myosin head are thought to affect the ATPase and actin-binding properties of the molecule. To date, however, there are no reports of the molecular mechanism of pathogenesis for mutations in the rod region of muscle myosins. Here, we present analysis of 4 mutations responsible for MSM: L1793P, R1845W, E1886K, and H1901L. We show that each MSM mutation has a different molecular phenotype, suggesting that there are multiple mechanisms by which MSM can be caused. These mechanisms range from thermodynamic and functional irregularities of individual proteins (L1793P), to varying defects in the assembly and stability of filaments formed from the proteins (R1845W, E1886K, and H1901L). In addition to furthering our understanding of MSM, these observations provide the first insight into how mutations affect the rod region of muscle myosins, and provide a framework for future studies of disease-causing mutations in this region of the molecule.

Download full-text

Full-text

Available from: Leslie A Leinwand, Jul 01, 2015
0 Followers
 · 
80 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The congenital myopathies are a diverse group of genetic skeletal muscle diseases, which typically present at birth or in early infancy. There are multiple modes of inheritance and degrees of severity (ranging from foetal akinesia, through lethality in the newborn period to milder early and later onset cases). Classically, the congenital myopathies are defined by skeletal muscle dysfunction and a non-dystrophic muscle biopsy with the presence of one or more characteristic histological features. However, mutations in multiple different genes can cause the same pathology and mutations in the same gene can cause multiple different pathologies. This is becoming ever more apparent now that, with the increasing use of next generation sequencing, a genetic diagnosis is achieved for a greater number of patients. Thus, considerable genetic and pathological overlap is emerging, blurring the classically established boundaries. At the same time, some of the pathophysiological concepts underlying the congenital myopathies are moving into sharper focus. Here we explore whether our emerging understanding of disease pathogenesis and underlying pathophysiological mechanisms, rather than a strictly gene-centric approach, will provide grounds for a different and perhaps complementary grouping of the congenital myopathies, that at the same time could help instil the development of shared potential therapeutic approaches. Stemming from recent advances in the congenital myopathy field, five key pathophysiology themes have emerged: defects in (i) sarcolemmal and intracellular membrane remodelling and excitation-contraction coupling; (ii) mitochondrial distribution and function; (iii) myofibrillar force generation; (iv) atrophy; and (v) autophagy. Based on numerous emerging lines of evidence from recent studies in cell lines and patient tissues, mouse models and zebrafish highlighting these unifying pathophysiological themes, here we review the congenital myopathies in relation to these emerging pathophysiological concepts, highlighting both areas of overlap between established entities, as well as areas of distinction within single gene disorders. Published by Oxford University Press on behalf of the Guarantors of Brain 2014. This work is written by US Government employees and is in the public domain in the US.
    Brain 12/2014; 138(2). DOI:10.1093/brain/awu368 · 10.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Indicator dilution techniques used in conjunction with modern imaging techniques have been used to measure perfusion. The perfusion model developed in this report is developed from linear systems analysis of indicator dilution time concentration curves. Perfusion is equal to the ratio of fractional tissue blood volume to system mean transit time multiplied by correction factors accounting for indicator dispersion and small vessel hematocrit effects. These assumed effects can greatly influence the perfusion calculation. Without correcting for these effects erythocyte indicators overestimate blood volume and underestimate transit time resulting in a large overestimate of perfusion; while plasma labels slightly underestimate blood volume and transit time and therefore perfusion
    Engineering in Medicine and Biology Society, 1994. Engineering Advances: New Opportunities for Biomedical Engineers. Proceedings of the 16th Annual International Conference of the IEEE; 02/1994
  • [Show abstract] [Hide abstract]
    ABSTRACT: Electric powered wheelchairs may be susceptible to electromagnetic interference from emissions present in the ambient environment. The proliferation of personal communication devices and radio communication have increased the ambient level of electromagnetic energy. Power wheelchairs use a variety of control input devices, wiring looms, and controllers which may be influenced by electromagnetic interference. The user may be placed at risk if the wheelchair behaves erratically in some circumstances. Methods can be applied to measure susceptibility to electromagnetic interference and reduce adverse affects
    Engineering in Medicine and Biology Society, 1994. Engineering Advances: New Opportunities for Biomedical Engineers. Proceedings of the 16th Annual International Conference of the IEEE; 02/1994